Research programme: controlled release idiopathic pulmonary fibrosis therapeutic - IntelGenxAlternative Names: INT0024; INT0024/2010
Latest Information Update: 16 Jul 2016
Price : $50
At a glance
- Originator IntelGenx Corp.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Canada (PO, Controlled release)